{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"costeff","columns":[{"gene":"","key":"population-f42c7fd38134108b3eae","label":"3-methylglutaconic aciduria, type III","mondoId":"MONDO:0009787","onsetQualifier":null,"originColumnKey":"MONDO:0009787/OMIM:258501","originalViews":[{"key":"MONDO:0009787/OMIM:258501","label":"3-methylglutaconic aciduria, type III","scopeLabel":"OMIM:258501","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["1f106e2a43e68a5eb7157c373ef8fcd973d1c90fadcaed8a31e9ef002e290ddd","1f83987661f343f16767b5dd79d29c95d635bc9109eae514946b210b42a93b0e","5d3e55a04910ebdc353d8b3c60ea1a87aa36847df7b82d1be2ab9868146bc34a","686dd806a7df3dbffa62122092b6fd57a276775c7669e401b5d490f30c2fa240","68b38fdb7637a99fba5e5798ed05bea2915d55e6fadd00b6b5a8759c1193beec","9454360cfc3fe9590c70a516de5cdb6b3e117b00fea1be05cc4f82a5545a6613","9777cdceb3fa0b3ca8f04da2f2441023795765bde0c5af0968e178113c1f74e8","97eb9f5df28672bade8e5e5c8d29cc15baec9bb601a5a0a59619cacbd84c174a","a1cc39d552f07ea556ef614142c2098411653841bfec0a9a76709f827985ceae","a49562cfedbe7a20ea19e803883bfcfb6e51694b340aebe2c2878d2adc017f93","acd068458f8b2fe5a7cb3e37e6a81b0a6bdca46d1c7089ef8cbbf5d5430ce7a1","c0e983201250802030e25516036ce8f3b9a08d6d1658beea7755c985c269cca6","ddbc1b634e1146b7d8321c919ce3bf9b1791bb335c8b5bae294873e4357b049d"],"recordQualifiers":{},"scopeLabel":"OMIM:258501","sourceIds":["OMIM:258501"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."},{"gene":"","key":"population-2c4b2d306e720cffdb5a","label":"3-methylglutaconic aciduria type 3","mondoId":"MONDO:0009787","onsetQualifier":null,"originColumnKey":"MONDO:0009787/ORPHA:67047","originalViews":[{"key":"MONDO:0009787/ORPHA:67047","label":"3-methylglutaconic aciduria type 3","scopeLabel":"ORPHA:67047","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["0f94798b18f7fd16232a027917764c1581775b006d57218be48da4f6f5f2b74a","16f87fa5953a08fd8db87f6524099dfa8e8f241f4b3b446017d45bcfa27a420f","2a5c5f112d18fd9fbcb285eb60d57045c47b0fdf0e272dc95d7c41fe3d8200a6","3199668db7642f046d5794f12e29c14c069dac90fb7573ea1c84547b37507b4e","4326d46f89e572a60097b0517ed55314843f60b3279f364b40862d26fd5f0622","55d265e9d7fa3fe0cfc4eb7cfdbe5740094d9c403fc6f785885eb8bf33d6ba9c","93b534a990e163d29061be9beeb742dc17331a426e2ff1960cc4211d0876523c","bf2f5114f9582c710e8b7ac19e1338f432063b0ba3082c13e50d9e9264044750","f0bf15c51ea33b99ceec43d11e0e6af12e38246886cc6daec3b154b5ff98a3b0"],"recordQualifiers":{},"scopeLabel":"ORPHA:67047","sourceIds":["ORPHA:67047"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-f42c7fd38134108b3eae","population-2c4b2d306e720cffdb5a"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0003535","HP:0003344","HP:0002071","HP:0001251","HP:0003487","HP:0002072","HP:0001266"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":3,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":22,"sourceGroups":{"omim":7,"orphanet":9,"published":6}},"features":[{"hpoId":"HP:0003535","label":"3-Methylglutaconic aciduria","primary":true},{"hpoId":"HP:0003344","label":"3-Methylglutaric aciduria","primary":true},{"hpoId":"HP:0002071","label":"Abnormality of extrapyramidal motor function","primary":true},{"hpoId":"HP:0001251","label":"Ataxia","primary":true},{"hpoId":"HP:0003487","label":"Babinski sign","primary":true},{"hpoId":"HP:0002072","label":"Chorea","primary":true},{"hpoId":"HP:0001266","label":"Choreoathetosis","primary":true},{"hpoId":"HP:0100543","label":"Cognitive impairment","primary":false},{"hpoId":"HP:0001260","label":"Dysarthria","primary":false},{"hpoId":"HP:0001288","label":"Gait disturbance","primary":false},{"hpoId":"HP:0001347","label":"Hyperreflexia","primary":false},{"hpoId":"HP:0001249","label":"Intellectual disability","primary":false},{"hpoId":"HP:0000639","label":"Nystagmus","primary":false},{"hpoId":"HP:0000648","label":"Optic atrophy","primary":false},{"hpoId":"HP:0007663","label":"Reduced visual acuity","primary":false},{"hpoId":"HP:0002313","label":"Spastic paraparesis","primary":false},{"hpoId":"HP:0001257","label":"Spasticity","primary":false},{"hpoId":"HP:0000505","label":"Visual impairment","primary":false}],"ledeHtml":"3-methylglutaconic aciduria type III (MGA III) is an organic aciduria characterised by the association of optic atrophy and choreoathetosis with 3-methylglutaconic aciduria.","mondoId":"MONDO:0009787","node":{"canonicalSlug":"costeff","comparisons":[{"documentSha256":"87694b97018f3e78011767322bb22885ecded08469d75afd792e804d77866860","key":"legacy-costeff","kind":"legacy","label":"3-methylglutaconic aciduria type 3","memberIds":["MONDO:0009787"],"mondoId":"MONDO:0009787","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/costeff.87694b97018f3e78011767322bb22885ecded08469d75afd792e804d77866860.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"definition-only","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"3-Methylglutaconic aciduria type 3","originalSourceId":"ORPHA:67047","paragraphs":["3-methylglutaconic aciduria type III (MGA III) is an organic aciduria characterised by the association of optic atrophy and choreoathetosis with 3-methylglutaconic aciduria."],"rawAttribution":"MONDO:0009787","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-21T17:05:34Z","upstream":"MONDO:0009787","url":"https://rarediseases.info.nih.gov/diseases/5663"},"ownColumnKeys":["population-f42c7fd38134108b3eae","population-2c4b2d306e720cffdb5a"],"publication":"published","relationships":[{"kind":"parent","label":"3-methylglutaconic aciduria","mondoId":"MONDO:0017359","slug":"3-methylglutaconic-aciduria"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"synonym-scope-not-retained","source":"MedlinePlus","url":"https://medlineplus.gov/genetics/condition/costeff-syndrome"}],"translation":"pending"},"records":[{"frequencyKind":"range","key":"0f94798b18f7fd16232a027917764c1581775b006d57218be48da4f6f5f2b74a","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001249","is_excluded":false,"label":"Intellectual disability","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"16f87fa5953a08fd8db87f6524099dfa8e8f241f4b3b446017d45bcfa27a420f","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0003535","is_excluded":false,"label":"3-Methylglutaconic aciduria","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"1f106e2a43e68a5eb7157c373ef8fcd973d1c90fadcaed8a31e9ef002e290ddd","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0001251","is_excluded":false,"label":"Ataxia","onset_id":null,"reference":"PMID:11668429","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"1f83987661f343f16767b5dd79d29c95d635bc9109eae514946b210b42a93b0e","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002072","is_excluded":false,"label":"Chorea","onset_id":null,"reference":"OMIM:258501","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"2a5c5f112d18fd9fbcb285eb60d57045c47b0fdf0e272dc95d7c41fe3d8200a6","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001266","is_excluded":false,"label":"Choreoathetosis","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"3199668db7642f046d5794f12e29c14c069dac90fb7573ea1c84547b37507b4e","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0002313","is_excluded":false,"label":"Spastic paraparesis","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"4326d46f89e572a60097b0517ed55314843f60b3279f364b40862d26fd5f0622","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001288","is_excluded":false,"label":"Gait disturbance","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"55d265e9d7fa3fe0cfc4eb7cfdbe5740094d9c403fc6f785885eb8bf33d6ba9c","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001251","is_excluded":false,"label":"Ataxia","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"5d3e55a04910ebdc353d8b3c60ea1a87aa36847df7b82d1be2ab9868146bc34a","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0100543","is_excluded":false,"label":"Cognitive impairment","onset_id":null,"reference":"OMIM:258501","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"686dd806a7df3dbffa62122092b6fd57a276775c7669e401b5d490f30c2fa240","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0001257","is_excluded":false,"label":"Spasticity","onset_id":null,"reference":"PMID:11668429","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"68b38fdb7637a99fba5e5798ed05bea2915d55e6fadd00b6b5a8759c1193beec","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001260","is_excluded":false,"label":"Dysarthria","onset_id":null,"reference":"OMIM:258501","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"93b534a990e163d29061be9beeb742dc17331a426e2ff1960cc4211d0876523c","raw":{"aspect":"P","body_system":"eye","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0000639","is_excluded":false,"label":"Nystagmus","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"count","key":"9454360cfc3fe9590c70a516de5cdb6b3e117b00fea1be05cc4f82a5545a6613","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"PCS","frequency_raw":"10/10","hpo_id":"HP:0003344","is_excluded":false,"label":"3-Methylglutaric aciduria","onset_id":null,"reference":"PMID:11668429","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"9777cdceb3fa0b3ca8f04da2f2441023795765bde0c5af0968e178113c1f74e8","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"PCS","frequency_raw":"10/10","hpo_id":"HP:0000648","is_excluded":false,"label":"Optic atrophy","onset_id":null,"reference":"PMID:11668429","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"97eb9f5df28672bade8e5e5c8d29cc15baec9bb601a5a0a59619cacbd84c174a","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0007663","is_excluded":false,"label":"Reduced visual acuity","onset_id":null,"reference":"OMIM:258501","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"a1cc39d552f07ea556ef614142c2098411653841bfec0a9a76709f827985ceae","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"PCS","frequency_raw":"10/10","hpo_id":"HP:0003535","is_excluded":false,"label":"3-Methylglutaconic aciduria","onset_id":null,"reference":"PMID:11668429","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"a49562cfedbe7a20ea19e803883bfcfb6e51694b340aebe2c2878d2adc017f93","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"PCS","frequency_raw":null,"hpo_id":"HP:0002071","is_excluded":false,"label":"Abnormality of extrapyramidal motor function","onset_id":null,"reference":"PMID:11668429","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"acd068458f8b2fe5a7cb3e37e6a81b0a6bdca46d1c7089ef8cbbf5d5430ce7a1","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003487","is_excluded":false,"label":"Babinski sign","onset_id":null,"reference":"OMIM:258501","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"bf2f5114f9582c710e8b7ac19e1338f432063b0ba3082c13e50d9e9264044750","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001260","is_excluded":false,"label":"Dysarthria","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"c0e983201250802030e25516036ce8f3b9a08d6d1658beea7755c985c269cca6","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001347","is_excluded":false,"label":"Hyperreflexia","onset_id":null,"reference":"OMIM:258501","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"ddbc1b634e1146b7d8321c919ce3bf9b1791bb335c8b5bae294873e4357b049d","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:258501","disease_name":"3-methylglutaconic aciduria, type III","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000505","is_excluded":false,"label":"Visual impairment","onset_id":null,"reference":"OMIM:258501","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"f0bf15c51ea33b99ceec43d11e0e6af12e38246886cc6daec3b154b5ff98a3b0","raw":{"aspect":"P","body_system":"eye","disease_id":"ORPHA:67047","disease_name":"3-methylglutaconic aciduria type 3","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0000505","is_excluded":false,"label":"Visual impairment","onset_id":null,"reference":"ORPHA:67047","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/5663\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0009787\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>definition-only</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>MONDO:0009787</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>3-methylglutaconic aciduria type III (MGA III) is an organic aciduria characterised by the association of optic atrophy and choreoathetosis with 3-methylglutaconic aciduria.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/5663\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Brief description"}],"sharedSources":[],"slug":"costeff","sourceDocuments":[{"name":"GARD: 3-Methylglutaconic aciduria type 3","reviewed":null,"source_release":"2026-10-21T17:05:34Z","url":"https://rarediseases.info.nih.gov/diseases/5663"},{"name":"MONDO: 3-methylglutaconic aciduria type 3","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0009787"}],"sourceNote":"","synonyms":["3-alpha methylglutaconic aciduria type III","3-methylglutaconic aciduria caused by mutation in OPA3","3-methylglutaconic aciduria, type III","autosomal recessive optic atrophy plus syndrome","autosomal recessive optic atrophy type 3","Costeff optic atrophy syndrome","Costeff syndrome","infantile optic atrophy with chorea and spastic paraplegia","Iraqi Jewish optic atrophy plus","MGA type III","MGA3","MGCA3","OPA3 3-methylglutaconic aciduria","optic atrophy infantile with chorea and spastic paraplegia"],"takeawayHtml":"","title":"3-methylglutaconic aciduria type 3"},"schemaVersion":1}
